American Journal of Hematology · 2000 · 14 citations · 12 references
MedicineHematologyPathologyClinical BiochemistryHematopathologyHemostasisCoagulation AbnormalitiesCoagulation DisordersCoagulation Factor DeficienciesCoagulation PhysiologyHemostatic DisordersThrombosisBleedingClinical Laboratory EvaluationCoagulationCoagulation DysregulationFactor Viii ActivationFactor Viii AlterationsLaboratory Test EvaluationNatural Anticoagulant Proteins
We report a case of Waldenström's macroglobulinemia with prominent bleeding tendency; laboratory investigation revealed an elevated activated partial thromboplastin time. Further laboratory evaluation showed circulating factor VIII anticoagulant, deemed polyclonal IgG, with a titer of 700 Bethesda Units/ml. The factor VIII inactivation kinetics of the patient plasma were identical to those of a type II inhibitor, and the inhibitor was found to recognize the A2 domain of the factor VIII heavy chain. Apparently, paraprotein is not always the cause of reduced activity of coagulation factors in neoplastic dysproteinemias.
12
Proceedings: A more uniform measurement of factor VIII inhibitors.
Kasper Ck, L. M. Aledort, Diane D. Aronson et al. · PubMed · 1975 · 352 citations
Shirley P. Levine · JAMA · 1995 · 182 citations